NATi is a national platform to build key capabilities and accelerate nucleic acid (RNA) therapeutics commercialisation in Singapore 

• Acts as a nexus to connect RNA researchers and clinicians with industry partners with built-in preparedness and resilience against future pandemics 
• Comprises of:
  • NATX funds* the development of novel chemistries, payload design, and delivery systems to improve safety, cell/tissue targeting and efficacy.   
  • RNA Foundry funds* the establishment of physical capabilities to test-bed new processes, enable end-to-end manufacturing, and provide quality materials for preclinical studies. 

 *Singapore universities and research institutions